tetano
Editor, Senior Moderator
Int J Pept Res Ther
. 2022;28(1):37.
doi: 10.1007/s10989-021-10348-z. Epub 2022 Jan 3.
In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein
Gunderao H Kathwate[SUP] 1 [/SUP]
Affiliations
Abstract
COVID 19 is a disease caused by a novel coronavirus, SARS-CoV2 originated in China most probably of Bat origin. Multiepitopes vaccine would be useful in eliminating SARS-CoV2 infections as asymptomatic patients are in large numbers. In response to this, we utilized bioinformatic tools to develop an efficient vaccine candidate against SARS-CoV2. The designed vaccine has effective BCR and TCR epitopes screened from the sequence of S-protein of SARS-CoV2. Predicted BCR and TCR epitopes found antigenic, non-toxic and probably non-allergen. Modeled and the refined tertiary structure predicted as valid for further use. Protein-Protein interaction prediction of TLR2/4 and designed vaccine indicates promising binding. The designed multiepitope vaccine has induced cell-mediated and humoral immunity along with increased interferon-gamma response. Macrophages and dendritic cells were also found to increase upon the vaccine exposure. In silico codon optimization and cloning in expression vector indicates that the vaccine can be efficiently expressed in E. coli. In conclusion, the predicted vaccine is a good antigen, probable no allergen, and has the potential to induce cellular and humoral immunity.
Keywords: B cell epitopes; COVID19; Immune-simulation; SARS-CoV2; T cell epitopes; Vaccine.
. 2022;28(1):37.
doi: 10.1007/s10989-021-10348-z. Epub 2022 Jan 3.
In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein
Gunderao H Kathwate[SUP] 1 [/SUP]
Affiliations
- PMID: 35002585
- PMCID: PMC8722413
- DOI: 10.1007/s10989-021-10348-z
Abstract
COVID 19 is a disease caused by a novel coronavirus, SARS-CoV2 originated in China most probably of Bat origin. Multiepitopes vaccine would be useful in eliminating SARS-CoV2 infections as asymptomatic patients are in large numbers. In response to this, we utilized bioinformatic tools to develop an efficient vaccine candidate against SARS-CoV2. The designed vaccine has effective BCR and TCR epitopes screened from the sequence of S-protein of SARS-CoV2. Predicted BCR and TCR epitopes found antigenic, non-toxic and probably non-allergen. Modeled and the refined tertiary structure predicted as valid for further use. Protein-Protein interaction prediction of TLR2/4 and designed vaccine indicates promising binding. The designed multiepitope vaccine has induced cell-mediated and humoral immunity along with increased interferon-gamma response. Macrophages and dendritic cells were also found to increase upon the vaccine exposure. In silico codon optimization and cloning in expression vector indicates that the vaccine can be efficiently expressed in E. coli. In conclusion, the predicted vaccine is a good antigen, probable no allergen, and has the potential to induce cellular and humoral immunity.
Keywords: B cell epitopes; COVID19; Immune-simulation; SARS-CoV2; T cell epitopes; Vaccine.